The age of the
mind-machine
is here.
The future of consciousness, tracked daily.
Neurotechnology is rewriting what it means to be human — and what it means to be intelligent. We track the companies, breakthroughs, and ideas at this frontier, so you don't miss a moment of the most important shift in the history of mind.
563+
Companies tracked
across 9 categories
$18B+
VC invested
in the field globally
24+
Articles published
research & industry
Every Sunday
Weekly digest
NeuroTech Digest
"The question is no longer whether machines can think —
but whether they can learn to love."
Browse by category
View all 563 companies →Featured companies
COMPASS Pathways
Psychedelics
COMPASS Pathways is a mental health care company focused on accelerating patient access to psilocybin therapy, with their proprietary COMP360 psilocybin formulation in Phase 3 trials for treatment-resistant depression. They are one of the most advanced and well-funded psychedelic medicine companies globally.
Kernel
Research Tools
Kernel builds non-invasive neuroimaging helmets — the Flow (TD-fNIRS) and Flux (MEG) systems — designed to make high-resolution brain scanning accessible outside of hospital settings. Founded by Bryan Johnson, the company aims to democratize neuroscience research and brain measurement at scale.
MindMed
Psychedelics
MindMed is a clinical-stage psychedelic medicine company developing novel therapeutics derived from LSD, MDMA, and ibogaine analogs for neurological and psychiatric disorders. Their lead asset MM120 (LSD tartrate) has shown promising Phase 2b results for generalized anxiety disorder.
Recently added
Funding spotlight
BrainPatch
Private
HABS - Human Augmented Brain System
Private
Lacework
Private
Neuralace Medical®
Private
NeuroStim TMS Centers
Private
Advanced NeuroFeedback & NeuroSkilling GmbH
Private
Latest news
FacialDx analyzes over 13,000 facial variables and 155 biomarkers to deliver neurological wellness indicators in seconds — giving clinicians objective data for sideline concussion decisions.
MIT's new EEG-based system decodes six discrete emotional states in real time with 94% accuracy, a landmark for non-invasive affective neuroscience.
Synchron's Stentrode Home Edition brings endovascular BCI technology to approved patients outside hospital walls for the first time.
Synchron's implantable brain-computer interface has now been placed in 100 patients globally, setting the stage for a pivotal FDA trial later this year.
A 24-month adaptive DBS trial reports significant memory retention improvements in early-stage Alzheimer's patients, reshaping neuromodulation research.
The FDA's finalized guidance on adaptive neural devices establishes new evidentiary standards for BCI approvals, reshaping the regulatory landscape.
Every Sunday
The NeuroTech Digest
Funding rounds, breakthroughs, and top jobs — curated weekly for industry professionals.
Subscribe free →For companies
Reach neurotech decision-makers
Premium listings, newsletter sponsorships, and featured placements.
View packages →News & insights
All articles →
ProductIt's Finally Here: FacialDx, an AI-Powered Support Tool for Sideline Concussion Assessments
FacialDx analyzes over 13,000 facial variables and 155 biomarkers to deliver neurological wellness indicators in seconds — giving clinicians objective data for sideline concussion decisions.
2026-06-23
ResearchMIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% Accuracy
MIT's new EEG-based system decodes six discrete emotional states in real time with 94% accuracy, a landmark for non-invasive affective neuroscience.
2026-06-13
ProductSynchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical Settings
Synchron's Stentrode Home Edition brings endovascular BCI technology to approved patients outside hospital walls for the first time.
2026-06-11
IndustrySynchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial
Synchron's implantable brain-computer interface has now been placed in 100 patients globally, setting the stage for a pivotal FDA trial later this year.
2026-06-09
ResearchClosed-Loop Deep Brain Stimulation Demonstrates Sustained Cognitive Benefits in Landmark Alzheimer's Trial
A 24-month adaptive DBS trial reports significant memory retention improvements in early-stage Alzheimer's patients, reshaping neuromodulation research.
2026-06-04
PolicyFDA Finalizes Guidance Framework for Adaptive Neural Devices, Setting Clearer Path for BCI Approvals
The FDA's finalized guidance on adaptive neural devices establishes new evidentiary standards for BCI approvals, reshaping the regulatory landscape.
2026-05-30
The field, by the numbers
563+
Companies mapped
across 9 sectors
$18B+
VC invested
in the field globally
3×/week
News published
Mon · Wed · Fri
8+
Articles
research & industry
Companies by sector
22
Brain-Computer
11
Cognitive
40
Mental
34
Neuromodulation
29
Neuropharmaceuticals
17
Neurodiagnostics
11
Research
12
Neurofeedback
40
Psychedelics
The NeuroTech Digest
The signal through the noise — breakthroughs, funding, and ideas at the edge of mind and machine. Curated weekly.
No spam. Unsubscribe anytime.